156 results
Page 3 of 8
8-K
EX-99.1
fy7mbb 70ve57h
5 May 20
Other Events
7:30am
8-K
EX-99.1
a83geb32wl
30 Apr 20
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD
7:31am
8-K
EX-99.1
srcxi9kdmdsp h5xd6up
3 Mar 20
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results
7:22am
8-K
EX-99.2
ev1fycp y6fwmm
9 Dec 19
Other Events
8:15am
8-K
EX-99.1
waxr 6aluhx1f
9 Dec 19
Other Events
8:15am
8-K
EX-99.1
2vujnoa8klzx
12 Nov 19
TG Therapeutics Provides Business Update and Reports Third Quarter 2019 Financial Results
7:39am
8-K
EX-99.1
xqlpe3
28 Oct 19
Umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports TG plans to present the data at a future medical conference and discuss the results with the FDA
7:59am
8-K
EX-99.1
2jllassp5k7gqwhy4qa
12 Sep 19
Other Events
9:25am
8-K
EX-99.1
sq672p 7bqq
9 Aug 19
Results of Operations and Financial Condition
7:33am
8-K
EX-99.1
z5vzx
10 May 19
TG Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results
7:01am
8-K
EX-99.1
i9ha3t
8 May 19
Ublituximab treatment continues to be well tolerated with a median duration of follow-up of 97.5 weeks
12:00am
8-K
EX-99.1
xn5t2 03s
1 Apr 19
Other Events
8:33am
424B5
0lnu0 2if6m
5 Mar 19
Prospectus supplement for primary offering
9:01am
424B5
ze27n
28 Feb 19
Prospectus supplement for primary offering
4:02pm
8-K
EX-99.1
wxz5fzdfqc a5jv
28 Feb 19
Other Events
7:33am